The effect of two golimumab doses on radiographic progression in ankylosing spondylitis: Results through 4 years of the GO-RAISE trial

Annals of the Rheumatic Diseases

Volumn 73, Issue 6, 2014, Pages 1107-1113

  Braun, Jürgen ^a   Baraliakos, Xenofon ^a   Hermann, Kay Geert A ^b   Deodhar, Atul ^c   Van Der Heijde, Désirée ^d   Inman, Robert ^e   Beutler, Anna ^f   Zhou, Yiying ^f   Xu, Stephen ^f   Hsu, Benjamin ^f  

^a RHEUMAZENTRUM RUHRGEBIET   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^d LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^e UNIVERSITY OF TORONTO   (Canada)

^f JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; GOLIMUMAB; PLACEBO;

ANKYLOSING SPONDYLITIS; ARTICLE; CERVICAL SPINE; CONTROLLED STUDY; DISEASE COURSE; DRUG DOSE INCREASE; HUMAN; LUMBAR SPINE; MAJOR CLINICAL STUDY; MODIFIED STOKE ANKYLOSING SPONDYLITIS SPINE SCORE; MULTICENTER STUDY (TOPIC); OSTEOPHYTE; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCORING SYSTEM; SPINE RADIOGRAPHY; SYNDESMOPHYTE;

ANKYLOSING SPONDYLITIS; ANTI-TNF; SPONDYLOARTHRITIS; TNF-ALPHA;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; CERVICAL VERTEBRAE; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; HUMANS; LONGITUDINAL STUDIES; LUMBAR VERTEBRAE; SPONDYLITIS, ANKYLOSING; TREATMENT OUTCOME;

EID: 84899971267     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2012-203075     Document Type: Article

References (17)

1. Schett G, Coates LC, Ash ZR, et al. Structural damage in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: traditional views, novel insights gained from TNF blockade, and concepts for the future. Arthritis Res Ther 2011;13(Suppl 1):S4.
2. Landewé R, Dougados M, Mielants H, et al. Physical function in ankylosing spondylitis is independently determined by both disease activity and radiographic damage of the spine. Ann Rheum Dis 2009;68: 863-7.
3. van der Heijde D, Salonen D, Weissman BN, et al.; for the Canadian (M03-606) study group and the ATLAS study group. Assessment of radiographic progression in the spines of patients with ankylosing spondylitis treated with adalimumab for up to 2 years. Arthritis Res Ther 2009;11:R127.
4. van der Heijde D, Landewé R, Einstein S, et al. Radiographic progression of ankylosing spondylitis after up to two years of treatment with etanercept. Arthritis Rheum 2008;58: 1324-31. (Pubitemid 351705922)
5. van der Heijde D, Landewé R, Baraliakos X, et al.; the Ankylosing Spondylitis Study for the Evaluation of Recombinant Infliximab Therapy Study Group. Radiographic findings following two years of infliximab therapy in patients with ankylosing spondylitis. Arthritis Rheum 2008;58: 3063-70.
6. Baraliakos X, Listing J, Brandt J, et al. Radiographic progression in patients with ankylosing spondylitis after 4 yrs of treatment with the anti-TNF-α antibody infliximab. Rheumatology (Oxford) 2007;46: 1450-3. (Pubitemid 47317093)
7. Inman RD, Davis JC Jr, van der Heijde D, et al. Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial. Arthritis Rheum 2008;58: 3402-12.
8. Braun J, Deodhar A, Inman RD, et al. Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 104-week results of the GO-RAISE study. Ann Rheum Dis 2012;71: 661-7.
9. van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis: a proposal for modification of the New York criteria. Arthritis Rheum 1984;27: 361-8. (Pubitemid 14134775)
10. Garrett S, Jenkinson T, Kennedy LG, et al. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994;21: 2286-91.
11. Creemers MCW, Franssen MJAM, van't Hof MA, et al. Assessment of outcome in ankylosing spondylitis: an extended radiographic scoring system. Ann Rheum Dis 2005;64: 127-9. (Pubitemid 40075289)
12. Baraliakos X, Listing J, Rudwaleit M, et al. Progression of radiographic damage in patients with ankylosing spondylitis: defining the central role of syndesmophytes. Ann Rheum Dis 2007;66: 910-15. (Pubitemid 46999792)
13. Lories R. The balance of tissue repair and remodeling in chronic arthritis. Nat Rev Rheumatol 2011;7: 700-7.
14. Visvanathan S, Wagner C, Marini JC, et al. Inflammatory biomarkers, disease activity and spinal disease measures in patients with ankylosing spondylitis after treatment with infliximab. Ann Rheum Dis 2008;67: 511-17. (Pubitemid 351498433)
15. Sieper J, Baraliakos X, Listing J, et al. Persistent reduction of spinal inflammation as assessed by magnetic resonance imaging in patients with ankylosing spondylitis after 2 yrs of treatment with the anti-tumour necrosis factor agent infliximab. Rheumatology (Oxford) 2005;44: 1525-30. (Pubitemid 41742469)
16. Haroon N, Maksymowych WP, Rahman P, et al. Radiographic severity of ankylosing spondylitis is associated with polymorphism of the large multifunctional peptidase 2 gene in the Spondyloarthritis Research Consortium of Canada Cohort. Arthritis Rheum 2012;64: 1119-26.
17. Maksymowych WP, Morency N, Conner-Spady B, et al. Suppression of inflammation and effects on new bone formation in ankylosing spondylitis: evidence for a window of opportunity in disease modification. Ann Rheum Dis. 2013;72: 23-8.